Enrollment Open for COURAGE-ALS Trial of Reldesemtiv

Enrollment Open for COURAGE-ALS Trial of Reldesemtiv

301747

Enrollment Open for COURAGE-ALS Trial of Reldesemtiv

Patient enrollment has begun for Cytokinetics‘ pivotal Phase 3 clinical trial investigating reldesemtiv for the treatment of people with early amyotrophic lateral sclerosis (ALS). The global COURAGE-ALS trial (NCT04944784) will enroll approximately 555 adults who are within two years of their first symptom of muscle weakness. Participants must have moderate lung function loss and mild disability, which is defined as an ALS Functional Rating Scale Revised (ALSFRS-R) score of no more than 44 at the…

You must be logged in to read/download the full post.